AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.375

+0.0051.35%

Volume:1.40M

Turnover:526.96K

Market Cap:552.65M

PE:-8.89

High:0.380

Open:0.370

Low:0.370

Close:0.370

52wk High:0.470

52wk Low:0.222

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.57

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.042

EPS(LYR):-0.042

ROE:-36.88%

ROA:-22.66%

PB:3.85

PE(LYR):-8.89

Loading ...

Overview Company News Filings

Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs

Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc

THOMSON REUTERS

Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial

MT Newswires Live

Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January

MT Newswires Live

BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update

Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study

THOMSON REUTERS

Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026

THOMSON REUTERS

Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile

THOMSON REUTERS

Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial

MT Newswires Live

Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial

MT Newswires Live

Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial

ASX Penny Stocks Spotlight: DUG Technology Among 3 Noteworthy Picks

Simply Wall St.

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Simply Wall St.

BUZZ-Australia's Immutep soars on partnering with India's Dr. Reddy’s

Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary

MT Newswires Live

Immutep And Dr. Reddy's Enters Into Strategic Collaboration For Commercialisation Of An Innovative Oncology Drug, Eftilagimod Alfa

Immutep Ltd - DR. Reddy's Receives Exclusive Rights for Eftilagimod Alfa in All Countries Outside North America, Europe, Japan, & Greater China

THOMSON REUTERS

Immutep and DR. Reddy’s Enters Into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

THOMSON REUTERS

Immutep Ltd - to Receive USD 20 Mln Upfront and up to USD 349.5 Mln

THOMSON REUTERS

Immutep Signs Licensing Agreement with Dr. Reddy's for Efti Commercialisation Outside North America, Europe, and Japan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.375,"timestamp":1770700320000,"preClose":0.37,"halted":0,"volume":1402062,"delay":0,"changeRate":0.013513513513513526,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"02-10 16:12:00 AEDT","open":0.37,"high":0.38,"low":0.37,"amount":526962,"amplitude":0.027027,"askPrice":0.39,"askSize":25000,"bidPrice":0.375,"bidSize":72863,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.37,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.565696,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.565696,"shares":1473721306,"dividePrice":0,"high":0.38,"amplitude":0.027027,"preClose":0.37,"low":0.37,"week52Low":0.222,"pbRate":"3.85","psRate":"109.57","week52High":0.47,"institutionHeld":0,"latestPrice":0.375,"committee":0.489082,"eps":-0.042199,"divideRate":0,"volume":1402062,"delay":0,"ttmEps":-0.042199,"open":0.37,"prevYearClose":0.415,"prevWeekClose":0.365,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.4,"twentyDayClose":0.435,"sixtyDayClose":0.27,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610649614","title":"Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610649614?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:03","pubTimestamp":1770721384,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbbVDC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2609459560","title":"Immutep Achieves 50% Enrolment in Global Tacti-004 (Keynote-F91) Phase Iii Trial in 1L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459560?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:00","pubTimestamp":1770382800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA9XGGVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2609533421","title":"Immutep Reaches 50% Enrollment in TACTI‑004 Phase Three Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533421?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:21","pubTimestamp":1770333717,"startTime":"0","endTime":"0","summary":"Immutep  has achieved 50% of its patient enrollment target in the TACTI-004 phase three trial, testing eftilagimod alfa in combination with Merck's Keytruda and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer, according to a Friday Australian bourse filing.The trial has enrolled 378 patients across more than 140 sites in 27 countries, per the filing.It seeks to increase response rates to anti-PD-1 therapy across all PD-L1 levels while improving clinical outcomes and patient survival, the filing said.Patient enrollment and the scheduled futility analysis are proceeding as planned, with complete enrollment anticipated by the third quarter, the filling added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2607779506","title":"Immutep Receives AU$30 Million In Upfront Payment From Indian Drugmaker In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779506?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:42","pubTimestamp":1769658172,"startTime":"0","endTime":"0","summary":"Immutep  said it received around AU$30 million in upfront payment from Indian firm Dr. Reddy's Laboratories in January under its strategic collaboration for the commercialization of Eftilagimod Alfa, its drug candidate for the treatment of non-small cell lung cancer, according to a Thursday Australian bourse filing.The firm is eligible to receive up to around AU$528 million in potential milestones, plus royalties on commercial sales of the drug candidate.During the December 2025 quarter, its AIPAC-003 phase two/three trial in metastatic breast cancer enrolled 71 metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative/low patients, resistant to endocrine therapy, including cyclin-dependent kinase 4/6 inhibitors, or triple-negative breast cancer patients.Its shares fell 2% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2593545170","title":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545170?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:44","pubTimestamp":1766450664,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech fir","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT00R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2593487707","title":"Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487707?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2593487092","title":"Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487092?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2593487002","title":"Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487002?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2593711881","title":"Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593711881","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593711881?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:48","pubTimestamp":1766364498,"startTime":"0","endTime":"0","summary":"Immutep  said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.The firm's shares fell past 1% in recent trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2591967586","title":"Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591967586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591967586?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:48","pubTimestamp":1765846096,"startTime":"0","endTime":"0","summary":"Immutep  said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2591785026","title":"Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591785026","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591785026?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:56","pubTimestamp":1765842994,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL7RvJTk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2591691009","title":"ASX Penny Stocks Spotlight: DUG Technology Among 3 Noteworthy Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591691009?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:04","pubTimestamp":1765764296,"startTime":"0","endTime":"0","summary":"As Australian shares face a challenging start to the week, influenced by global tech sector declines, investors may find themselves exploring alternative opportunities within the market. Penny stocks, often representing smaller or newer companies, continue to capture interest despite their somewhat outdated label. By focusing on those with solid financial foundations and potential for growth, these stocks can offer surprising value and stability in uncertain times.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-wgn/wagners-holding-shares/news/asx-penny-stocks-spotlight-dug-technology-among-3-noteworthy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-wgn/wagners-holding-shares/news/asx-penny-stocks-spotlight-dug-technology-among-3-noteworthy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7132","BK7104","SSM.AU","BK7048","BK7016","BK7508","BK7506","BK7045","VRS.AU","BK7128","IGL.AU","BK7050","MTO.AU","DSK.AU","BK7067","BK7055","WAF.AU","BK7111","DUG.AU","GWA.AU","BK7044","BK7077","EDU.AU","BK7012","EZZ.AU","IMM.AU","WGN.AU","AAL.AU","BK7143"],"gpt_icon":0},{"id":"2590536261","title":"Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2590536261","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590536261?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:25","pubTimestamp":1765365914,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway.\nSee our latest analysis for Immutep.\nThe recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-asximm-valuation-check-after-dr-reddys-licensing-dea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-asximm-valuation-check-after-dr-reddys-licensing-dea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2590539567","title":"BUZZ-Australia's Immutep soars on partnering with India's Dr. Reddy’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539567","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590539567?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:39","pubTimestamp":1765247968,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep soarson partnering with India's Dr. Reddy’s** Shares of Immutep IMM.AX rise as much as 31.4% to A$0.335, their biggest intraday pct gain since May 18, 2023** Biotech co partners with India's Dr. Reddy’s Laboratories REDY.NS for commercialization of Eftilagimod Alfa, an Oncology drug** Dr. Reddy’s receives exclusive rights to develop and commercialize the drug in all countries outside North America, Europe, Japan, and Greater China** Immutep will receive $20 million upfront, eligible for milestone payments of up to $349.5 million plus royalties on commercial sales** Shares hit highest level since May 6** YTD, IMM shares down 12.3%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL6N3XF05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2590641613","title":"Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2590641613","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590641613?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:41","pubTimestamp":1765237273,"startTime":"0","endTime":"0","summary":"Shares of Immutep  rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2589353262","title":"Immutep And Dr. Reddy's Enters Into Strategic Collaboration For Commercialisation Of An Innovative Oncology Drug, Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353262","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353262?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:16","pubTimestamp":1765199791,"startTime":"0","endTime":"0","summary":"Dec 8 (Reuters) - Immutep Ltd ::*IMMUTEP AND DR. REDDY’S ENTERS INTO STRATEGIC COLLABORATION FOR COMMERCIALISATION OF AN INNOVATIVE ONCOLOGY DRUG, EFTILAGIMOD ALFA*IMMUTEP LTD - TO RECEIVE USD 20 MILL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nRSD3Pt0D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2589538353","title":"Immutep Ltd - DR. Reddy's Receives Exclusive Rights for Eftilagimod Alfa in All Countries Outside North America, Europe, Japan, & Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=2589538353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589538353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1BK5F0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2589353859","title":"Immutep and DR. Reddy’s Enters Into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353859","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353859?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1BK5F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2589035383","title":"Immutep Ltd - to Receive USD 20 Mln Upfront and up to USD 349.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2589035383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589035383?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA1BK5F0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2589389338","title":"Immutep Signs Licensing Agreement with Dr. Reddy's for Efti Commercialisation Outside North America, Europe, and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389338","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589389338?lang=en_us&edition=fundamental","pubTime":"2025-12-08 16:03","pubTimestamp":1765180999,"startTime":"0","endTime":"0","summary":"Immutep Limited has announced a strategic collaboration and exclusive licensing agreement with Dr. Reddy's Laboratories for the development and commercialisation of Eftilagimod Alfa  in all countries outside North America, Europe, Japan, and Greater China. Under the terms of the agreement, Immutep will receive an upfront payment of USD 20 million and is eligible for potential regulatory development and commercial milestone payments of up to USD 349.5 million, in addition to double-digit royalties on commercial sales in the licensed markets. Dr. Reddy's receives exclusive rights to develop and commercialise efti in the specified territories, while Immutep retains full rights in North America, Europe, Japan, and Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3QM93K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}